You have to be a little careful on the 2016 as the next JJ crpc drug may be approved then. Don't forget to keep an eye on the the EXEL trial results in fall.
We need to see evidence that MDVN is stealing JNJ's growth. It that is shown decisively then this continues to be a buy otherwise it is a hold (for me at least)
and not too many of them!
Not an expert on these matters but looks like a good financing which we knew was coming. Hopefully pps moves up so next financing will be done at higher levels.
Patience is required. May take several years. Technology is just being now being adopted. DBS cracks the door open into the hospitals. Drug delivery is next. A successful clinical trial would be fantastic for drug delivery. Waiting on use cases for surgery.
That would be the time to buy. Currently management has very little cred.
Question. Are there any results from a previous Phase 1 that would indicate good/great results in the MS pain trail? This could be a minor catalyst for the stock and I believe it will be here before the lawsuit results are announced.
This board is an echo chamber for longs and at the same time infested with shorts.
Risk is they lose the court case, the PPS drops by 75% it's game over.
Reward is PPS rises 50% on a court victory (these are my guesstimates for this current time).
Will probably win but you need to consider how comfortable you are with the risk/reward.
All due respect I doubt there will be a settlement. The best biotech hedge funds have not bought in to AVNR to lose 70% in a couple of weeks.
amen to that BUT if the lying, stinking, vermin shorts would leave I think the cheerleaders would put down there pom-poms.
Increases : 1361380
Decreases : -150143
Owner Name Date Shared Held Change (Shares) Change(%) Value(in 1,000s)
AMERICAN INTERNATIONAL GROUP INC 9/30/2013 99,819 5,817 6.19 411
BLB&B ADVISORS, LLC 9/30/2013 12,500 12,500 New 52
COMMONWEALTH EQUITY SERVICES, INC 9/30/2013 68,785 942 1.39 283
CREATIVE PLANNING 9/30/2013 36,200 35,650 6,481.82 149
FRANKLIN STREET ADVISORS INC /NC 9/30/2013 65,000 65,000 New 268
MAZAMA CAPITAL MANAGEMENT INC 9/30/2013 9,132 9,132 New 38
METROPOLITAN LIFE INSURANCE CO/NY 9/30/2013 116,503 6,163 5.59 480
NATIONAL ASSET MANAGEMENT, INC. 9/30/2013 8,500 8,500 New 35
NATIONWIDE FUND ADVISORS 9/30/2013 115,669 6,638 6.09 477
NUVEEN ASSET MANAGEMENT, LLC 9/30/2013 11,218 1,168 11.62 46
PINNACLE ADVISORY GROUP, INC. 9/30/2013 24,500 24,500 New 101
PRINCIPAL FINANCIAL GROUP INC 9/30/2013 70,071 27,512 64.64 289
PROSHARE ADVISORS LLC 9/30/2013 142,756 20,703 16.96 588
PRUDENTIAL FINANCIAL INC 9/30/2013 15,869 500 3.25 65
REYNOLDS CAPITAL MANAGEMENT LLC 9/30/2013 14,800 14,800 New 61
SUNTRUST BANKS INC 9/30/2013 409,053 967 0.24 1,685
SWISS NATIONAL BANK 9/30/2013 126,500 8,500 7.2 521
TD ASSET MANAGEMENT INC 9/30/2013 437,100 41,300 10.44 1,801
TEACHER RETIREMENT SYSTEM OF TEXAS 9/30/2013 17,751 8,409 90.01 73
TEKLA CAPITAL MANAGEMENT LLC 9/30/2013 960,000 960,000 New 3,955
TOWER RESEARCH CAPITAL LLC 9/30/2013 8,414 8,394 41,970 35
VANGUARD GROUP INC 9/30/2013 4,209,657 94,285 2.29 17,344
BALLENTINE PARTNERS, LLC 9/30/2013 0 -30,000 Sold Out
JPMORGAN CHASE & CO 9/30/2013 86,905 -51,231 -37.09 358
PARAMETRIC PORTFOLIO ASSOCIATES LLC 9/30/2013 42,816 -1,234 -2.8 176
RHUMBLINE ADVISERS 9/30/2013 154,610 -102 -0.07 637
RUSSELL FRANK CO/ 9/30/2013 160,920 -32,516 -16.81 663
TDAM USA INC. 9/30/2013 0 -18,653 Sold Out
WEDBUSH MORGAN SECURITIES INC 9/30/2013 0 -15,013 Sold Out
WORLD ASSET MANAGEMENT INC 9/30/2013 11,401 -1,394 -10.9 47
From last quarter CC:
Let me take a minute to talk about financial values. As you may have seen in our earnings release this afternoon, this is the first quarter in which we are providing guidance for investors. In the first half of 2013, we achieved growth in product revenue of 87% as measured by the product revenues for the same period in 2012. We expect to see a similar growth rate in our product revenues in the third quarter of 2013 compared with the third quarter of 2012.
In the fourth quarter of 2013, we expect an increase in that growth rate as measured against our product revenue in the fourth quarter of 2012. We expect this acceleration in our growth rate in Q4 as we believe our current investment in sales and marketing capabilities will begin to pay off. Based on these expected growth rates, we anticipate total product revenues for 2013 of $2.3 million to $2.7 million, which would equate to total revenues for 2013 of $3.2 million to $3.6 million.
Now, I want to point out that these are product revenues projected by the Company for 2013 do not include significant revenues from drug delivery procedures, as the drug therapies being delivered with ClearPoint are in clinical trials and have not received regulatory approval.